Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2011.03.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular Hydrogen Therapy in Sjögren's Syndrome With Pulmonary Arterial Hypertension and Right-sided Heart Failure: A Case Report of Improved Immune Markers Including Treg, B Cells and Plasma Cell.
In Vivo
October 2024
Rheumatology/Immunology and Allergy, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C.
Background/aim: Connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) is a severe complication characterized by elevated pulmonary artery pressure, which can lead to right heart failure and death, if untreated. Standard treatments often fail to adequately manage symptoms, highlighting the need for novel therapeutic approaches. This study investigated the efficacy of molecular hydrogen (H) therapy in a patient with CTD-PAH.
View Article and Find Full Text PDFPulmonary artery denervation versus conventional therapies for PAH: a systematic review and updated network meta-analysis.
ESC Heart Fail
October 2024
Department of Biostatistics, School of Public Health, Center of Global Health, Nanjing Medical University, Nanjing, China.
Article Synopsis
- A recent study explores the effectiveness and safety of a new therapy for pulmonary artery hypertension called pulmonary artery denervation (PADN), which showed promise in lab trials.
- The researchers compared PADN to traditional therapies using data from various medical databases and past meta-analyses, focusing on outcomes such as walking distance and pulmonary artery pressure.
- Results indicated that PADN significantly improved walking distance compared to several conventional treatments and had lower risks of clinical worsening and rehospitalization.
Actigraphy methodology in the Kids Mod PAH trial: Physical activity as a functional endpoint in pediatric clinical trials.
Pulm Circ
January 2024
Section of Pediatric Cardiology, Morgan Stanley Children's Hospital of NY Presbyterian, Vagelos College of Physicians and Surgeons Columbia University New York New York USA.
Pulmonary vasodilator treatment can improve hemodynamics, right ventricular function, symptoms, and survival in pediatric pulmonary hypertension (PH). However, clinical trial data are lacking due to many constraints. One major limitation is the lack of relevant trial endpoints reflective of hemodynamics or functional status in patients in whom standard exercise testing is impractical, unreliable, or not reproducible.
View Article and Find Full Text PDFCurrent Management and Future Directions for Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.
J Pers Med
December 2023
Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.
Article Synopsis
- Advances in the management of congenital heart disease have led to increased survival rates for patients into adulthood, but this brings potential complications like pulmonary hypertension associated with congenital heart disease (PAH-CHD).
- PAH-CHD is a complex form of pulmonary hypertension that requires specialized care to enhance patients' quality of life and prognosis.
- While new treatments have improved outcomes for pulmonary arterial hypertension, the long-term effects on PAH-CHD patients are still unclear, highlighting the need for treatment plans based on healthcare providers' clinical experience.
Recent Advances in the Treatment of Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases.
Pharmaceuticals (Basel)
September 2023
1st Department of Cardiology, Poznan University of Medical Sciences, Długa 1/2 Street, 61-848 Poznan, Poland.
Article Synopsis
- * PAH-CTD is progressive and has a poor prognosis, highlighting the importance of early diagnosis and specific treatments available, such as various drug classes including prostacyclin derivatives and endothelin receptor antagonists.
- * The manuscript aims to review the latest advancements in treatment strategies, the mechanisms of PAH-targeted drugs, and ongoing research to improve outcomes for patients with PAH-CTD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!